# The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

> **NCT00777764** · PHASE4 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Healthy
- Asthma

## Interventions

- **DRUG:** Cohort I
- **DRUG:** Cohort 2

## Key facts

- **NCT ID:** NCT00777764
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00777764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00777764, "The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00777764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*